Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Patient research

- PMLiVE

Bristol Myers Squibb’s active ulcerative colitis treatment bags NICE recommendation

Phase 3 trial results of Zeposia showed statistically significant results in response and remission

New syndicated patient reports –

Living with Uterine Fibroids and Endometriosis US 2022

Research Partnership

Animation: Living With

The journey from the patient's perspective

Research Partnership

- PMLiVE

Sandoz’s biosimilar medicine application accepted by FDA

If approved, the higher concentration formulation could decrease the number of injections required for patients currently receiving a lower dose of Hyrimoz

Infographic: Therapy Watch Lupus

Download our latest infographic, which offers an introduction to the real-world patient insights collected by our Therapy Watch Lupus study.

Research Partnership

Article: Getting their lives back: Improving options for people with Lupus

Head of Therapy Watch, Helen Parfitt and Head of Living With, Mariel Metcalfe, investigate Lupus from the perspective of both healthcare professionals and patients using data from our syndicated products.

Research Partnership

RP Investigates – Q&A session: Living with Lupus

In this 45-minute session, Head of Living With, Mariel Metcalfe spoke to Brenda, who was diagnosed with Lupus 12 years ago.

Research Partnership

New syndicated patient report – Living with Lupus US

Living with Lupus US is a new syndicated patient report which offers valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs.

Research Partnership

Were patients at the heart of your New Year’s Resolutions?

Over recent years, many pharma companies have increasingly stated that they have patients at the heart of their success objectives... but if they were to look back and decide whether...

Origins – The Patient Focused Specialists

- PMLiVE

Pfizer buys Arena in $6.7bn deal to broaden immuno-inflammatory portfolio

The cash deal includes Arena’s lead candidate, etrasimod, which is currently in trials for ulcerative colitis, Crohn’s disease and atopic dermatitis

Events:

Patient Centricity and Engagement Conference 2021

Research Partnership

Article:

The disparity of patient experiences with Crohn’s Disease in Europe and Japan

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links